



# **STIC Search Report**

## **EIC 3700**

**STIC Database Tracking Number: 156498**

**TO: Darwin Erez**  
**Location: RND 6c70**  
**Art Unit: 3731**  
**Friday June 17, 2005**

**Case Serial Number: 09/967274**

**From: John Sims**  
**Location: EIC 3700**  
**RND 8B31**  
**Phone: 571 272-3507**

**john.sims@uspto.gov**

### **Search Notes**

Please examine your results carefully. Search terms are highlighted in boldface type.

**Erezo, Darwin**

---

**From:** Sims, John  
**Sent:** Friday, June 17, 2005 1:01 PM  
**To:** Erezo, Darwin  
**Subject:** 09/967,274--CO2 based bi-level CPAP control

Darwin--

We did a search on this method/device case (CPAP, CO2 sensing and CO2 threshold value) but did not find any good art.

I will provide a more complete report on Monday.

John Sims, Team Leader  
EIC 3700  
Randolph Bldg. 8b35  
571 272-3507

RUSH  
needs by noon 6/11  
Access DB# 156498

## SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: DARWIN EREZO Examiner #: 78496 Date: 6/14/05  
Art Unit: 3731 Phone Number: 30 24695 Serial Number: 60/967.274  
Mail Box and Bldg/Room Location: RANB 6070 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

\*\*\*\*\*

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: CARBON DIOXIDE - BASED BI-LEVEL CPAP CONTROL

Inventors (please provide full names): JOSEPH B. RICHIEY JR RICHIEY JR

Earliest Priority Filing Date: 09/28/2000

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

THIS IS A CPAP DEVICE (CONTINUOUS POSITIVE AIR PRESSURE)

- METHOD + DEVICE: BOTH ~~WAVE~~ SENSES CO2 LEVEL TO DETECT  
INTUSATION / EXHILATION

- THEN COMPARES THIS LEVEL TO A  
PREDETERMINED THRESHOLD VALUE.

- CLAIMS ARE ATTACHED.

\* This is an AF request.  
Please RUSH.

Ant. T. T. Nguyen  
SPE AC 3731.

### STAFF USE ONLY

Searcher: J Sim  
Searcher Phone #: 23507  
Searcher Location: RNO 8B35  
Date Searcher Picked Up: \_\_\_\_\_  
Date Completed: 6/17/05  
Searcher Prep & Review Time: \_\_\_\_\_  
Clerical Prep Time: \_\_\_\_\_  
Online Time: \_\_\_\_\_

### Type of Search

NA Sequence (#) \_\_\_\_\_  
AA Sequence (#) \_\_\_\_\_  
Structure (#) \_\_\_\_\_  
Bibliographic ☒  
Litigation \_\_\_\_\_  
Fulltext ☒  
Patent Family \_\_\_\_\_  
Other \_\_\_\_\_

### Vendors and cost where applicable

STN ☒  
Dialog ☒  
Questel/Orbit \_\_\_\_\_  
Dr. Link \_\_\_\_\_  
Lexis/Nexis \_\_\_\_\_  
Sequence Systems \_\_\_\_\_  
WWW/Internet \_\_\_\_\_  
Other (specify) \_\_\_\_\_

23/3,K/18 (Item 1 from file: 266)

DIALOG(R) File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00481346

IDENTIFYING NO.: 144381; 0049; 607 AGENCY CODE: VA

**Effect of Continuous Positive Airway Pressure (CPAP) on Endothelial Function**

PRINCIPAL INVESTIGATOR: Skatrud, James B., M.D.

PERFORMING ORG.: Department of Veterans Affairs, Medical Center Madison, WI

SPONSORING ORG.: Department of Veterans Affairs, Research and Development (15), 810 Vermont Ave. N.W., Washington, D.C. 20420 United States of America

DATES: 20011107

**Effect of Continuous Positive Airway Pressure (CPAP) on Endothelial Function**

SUMMARY: SLEEP APNEA SYNDROMES; ENDOTHELIUM, VASCULAR; CEREBROVASCULAR CIRCULATION

OBJECTIVES: To determine whether elimination of sleep apnea with nasal **continuous positive airway pressure (CPAP)** improves vascular function in the forearm and cerebral circulation in patients with sleep apnea syndrome.

Research Design: This is a prospective, unblinded study.

METHODOLOGY: Twenty patients with recently diagnosed, moderate-to-severe sleep apnea (40-60 events per hour), in whom **CPAP** treatment is clinically indicated, will participate. Subjects must be normotensive (average blood pressure, **measured** on 3 separate screening visits less than 140/90) non-smokers. Subjects will be excluded if they have a history of diabetes mellitus, cerebrovascular disease, angina, myocardial infarction, ventricular dysfunction, or hyperlipidemia (defined as the 75th percentile for age and gender). Subjects with carotid bruits will also be excluded. Before **CPAP** treatment is initiated, cerebrovascular reactivity to **increases** and **decreases** in **carbon dioxide level (CO2)** will be **measured** noninvasively using Doppler ultrasound. This test involves breathing **increased** CO2 at 2 levels titrated to produce **increases** of +5 and +10 mmHg in end-tidal CO2 tension (5 minutes each) and the use of 2 levels of voluntary overbreathing to lower the...

... tension by -5 and -10 mmHg below baseline (5 minutes each). In another test on the same day, blood flow in the forearm will be **measured** noninvasively using Doppler ultrasound before and after vascular occlusion of the forearm (4.5 minutes) and administration of sublingual nitroglycerin. Both vascular studies will be repeated after 6 weeks of in-home **CPAP** treatment.

1/7/1

DIALOG(R) File 266:FEDRIP

Comp & dist by NTIS, Intl Copyright All Rights Res. All rts. reserv.

00481346

IDENTIFYING NO.: 144381; 0049; 607 AGENCY CODE: VA

**Effect of Continuous Positive Airway Pressure (\*CPAP\*) on \*Endothelial\*  
\*Function\***

PRINCIPAL INVESTIGATOR: Skatrud, James B., M.D.

PERFORMING ORG.: Department of Veterans Affairs, Medical Center Madison,  
WI

SPONSORING ORG.: Department of Veterans Affairs, Research and Development  
(15), 810 Vermont Ave. N.W., Washington, D.C. 20420 United States of  
America

DATES: 20011107

SUMMARY: SLEEP APNEA SYNDROMES; ENDOTHELIUM, VASCULAR; CEREBROVASCULAR  
CIRCULATION

OBJECTIVES: To determine whether elimination of sleep apnea with  
nasal continuous positive airway pressure (CPAP) improves vascular function  
in the forearm and cerebral circulation in patients with sleep apnea  
syndrome.

Research Design: This is a prospective, unblinded study.

METHODOLOGY: Twenty patients with recently diagnosed,  
moderate-to-severe sleep apnea (40-60 events per hour), in whom CPAP  
treatment is clinically indicated, will participate. Subjects must be  
normotensive (average blood pressure, measured on 3 separate screening  
visits less than 140/90) non-smokers. Subjects will be excluded if they  
have a history of diabetes mellitus, cerebrovascular disease, angina,  
myocardial infarction, ventricular dysfunction, or hyperlipidemia (defined  
as the 75th percentile for age and gender). Subjects with carotid bruits  
will also be excluded. Before CPAP treatment is initiated, cerebrovascular  
reactivity to increases and decreases in carbon dioxide level (CO2) will be  
measured noninvasively using Doppler ultrasound. This test involves  
breathing increased CO2 at 2 levels titrated to produce increases of +5 and  
+10 mmHg in end-tidal CO2 tension (5 minutes each) and the use of 2 levels  
of voluntary overbreathing to lower the end-tidal CO2 tension by -5 and -10  
mmHg below baseline (5 minutes each). In another test on the same day,  
blood flow in the forearm will be measured noninvasively using Doppler  
ultrasound before and after vascular occlusion of the forearm (4.5 minutes)  
and administration of sublingual nitroglycerin. Both vascular studies will  
be repeated after 6 weeks of in-home CPAP treatment.

?

18/7/1 (Item 1 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2005 BIOSIS. All rts. reserv.

0011218178 BIOSIS NO.: 199800012425

**Improvement of exercise performance with short-term nasal continuous positive airway pressure in patients with obstructive sleep apnea**

AUTHOR: Taguchi Osamu; Hida Wataru; Okabe Shinichi; Ebihara Satoru; Ogawa

Hiromasa; Kikuchi Yoshihiro; Shirato Kunio

AUTHOR ADDRESS: First Dep. Internal Med., Tohoku Univ. Sch. Med., 1-1 Seiryomachi, Aoba-ku, Sendai 980-77, Japan\*\*Japan

JOURNAL: Tohoku Journal of Experimental Medicine 183 (1): p45-53  
Sept.,

1997 1997

MEDIUM: print

ISSN: 0040-8727

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: We examined the effects of nasal **continuous positive airway**

**pressure ( CPAP )** on exercise performance in patients with obstructive

sleep apnea (OSA). Six patients were treated with nasal **CPAP** on seven

successive days and underwent overnight sleep studies and multiple sleep

latency test (MSLT) at the beginning and after the last day of the treatment. The subjects also performed incremental exercise testing using

a bicycle ergometer followed by 0-w, 25-w, 50-w, - (3 minutes each) until

maximum **level** . Arterial oxygen pressure, arterial **carbon dioxide**

pressure at rest while awake, apnea/hypopnea index, longest apnea duration, the lowest percutaneous oxygen saturation measured by a pulse

**oximeter** and the value of MSLT were significantly improved after nasal

**CPAP** . Moreover, maximal oxygen consumption was significantly increased

from 1841 ml/min+350 to 2125 ml/min+351 (p<0.05); however, other cardiorespiratory **parameters** did not change significantly. The improvement of exercise performance by short-term nasal **CPAP** treatment

in OSA patients may correlate with the improvement of sleepiness.

18/7/2 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)

(c) 2005 BIOSIS. All rts. reserv.

0006125148 BIOSIS NO.: 198885094039

**THE DOSE RESPONSE OF THEOPHYLLINE IN THE TREATMENT OF APNEA OF  
PREMATURITY**

AUTHOR: MUTTITT S C (Reprint); TIERNEY A J; FINER N N

AUTHOR ADDRESS: DEP NEWBORN MED, ROYAL ALEXANDRA GENERAL HOSP, 10240  
KINGSWAY AVE, EDMONTON, ALBERTA T5H 3V9, CAN\*\*CANADA

JOURNAL: Journal of Pediatrics 112 (1): p115-121 1988

ISSN: 0022-3476

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: ENGLISH

ABSTRACT: In an effort to establish the minimum effective dose of theophylline in the treatment of idiopathic apnea of prematurity, a prospective trial of 22 infants with at least 0.33 episodes of apnea per

hour were studied. Apnea was diagnosed exclusively by continuous recording of heart rate, respiratory impedance, end-tidal **CO2**, and either or both transcutaneous oxygen and pulse **oximetry**. Four discrete

serum concentrations of theophylline (23 .mu.mol/L or 4.2 mg/L, 47 .mu.mol/L or 8.5 mg/L, 70 .mu.mol/L or 12.7 mg/L, and 84 .mu.mol/L or

15.3 mg/L) were attained by using repeated loading doses of 4 mg/kg and

increasing the maintenance dose from 1 to 1.5 mg/kg to 2 to 2.5 mg/kg,

given every 8 hours. Before treatment and 24 hours after each loading

dose, airway occlusions and measures of tidal volume, minute ventilation,

and respiratory timing were performed. The effectiveness of therapy was

assessed by either a continuous computer data-acquisition system or paper

recording for the duration of the study. Of the 22 infants, three

responded at **level** 1, three at **level** 2, and 10 at **level** 3. One of

the four infants loaded to the fourth **level** had a sustained response

for a total cumulative response of 77%. The five remaining infants required additional treatment with doxapram or **continuous**

**positive**

**airway pressure**. There was a significant increase in inspiratory pressure 100 msec after airway occlusion, maximum inspiratory pressure

during airway occlusion, tidal volume, ratio of tidal volume to inspiratory time (mean inspiratory flow), and minute ventilation from the

pretreatment measurements to those at the maximum dose of theophylline.

The apnea response did not correlate with these improvements in

ventilation measures.

**18/7/3** (Item 1 from file: 34)  
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2005 Inst for Sci Info. All rts. reserv.

12591619 Genuine Article#: 803HB Number of References: 50

**Title: Neonatal resuscitation: raising the bar**

Author(s): Finer NN (REPRINT) ; Rich WD

Corporate Source: 200 W Arbor Dr/San Diego//CA/92103 (REPRINT); Univ Calif

San Diego, Med Ctr, Dept Pediat, Div Neonatol, San Diego//CA/92103  
Journal: CURRENT OPINION IN PEDIATRICS, 2004, V16, N2 (APR), P157-162  
ISSN: 1040-8703 Publication date: 20040400  
Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA

19106-3621 USA

Language: English Document Type: REVIEW

Abstract: Purpose of review To provide an overview of neonatal resuscitation practices with an emphasis on interventions that are not currently accepted or adapted into existing resuscitation guidelines.

Recent findings Current resuscitation guidelines do not contain specific guidelines for the approach to the extremely low birth weight infant. The differences in environment and management between the neonatal ICU and delivery room are striking and are magnified in the resuscitation of extremely low birth weight infants for whom maintenance of a neutral thermal environment is essential. The use of a polyethylene wrap applied at delivery has been shown to reduce the occurrence of hypothermia and decrease mortality. There is substantial evidence that term and near-term newborn infants can be effectively resuscitated with room air, and recent follow-up studies have demonstrated that this approach is not associated with increased significant differences in neurologic handicap, somatic growth, or developmental milestones when compared with the use of 100% oxygen. The safety and potential benefits of this approach require prospective evaluation in the premature and especially extremely low birth weight infant. There is preexisting evidence that demonstrates that the use of prolonged inflations and t-piece resuscitators may be advantageous during resuscitation, but not all guidelines support these interventions. Although regulated **continuous positive airway pressure**, pulse oximeters, and blenders are routinely used once

an  
infant is admitted to the neonatal ICU, none of these  
interventions is  
recommended in the delivery area. Although prospective studies  
have  
demonstrated that the use of colorimetric **CO2 detectors**  
significantly decreases the time to recognize misplaced  
endotracheal  
tubes placed during resuscitation, their use is not required by  
current  
guidelines. The duration of an intubation attempt during  
resuscitation  
had never been prospectively evaluated, and our recent findings  
suggest  
that a limit of 30 seconds is well tolerated and provides adequate  
time  
for a successful attempt.  
Summary There is significant potential for improvement in  
current  
resuscitation environments and interventions that will only be  
realized  
through further prospective research.

**18/7/4 (Item 2 from file: 34)**

DIALOG(R) File 34:SciSearch(R) Cited Ref Sci  
(c) 2005 Inst for Sci Info. All rts. reserv.

04816622 Genuine Article#: UJ946 Number of References: 36

**Title: FACE-STRAIGHT-DOWN AND FACE-NEAR-STRAIGHT-DOWN POSITIONS IN  
HEALTHY,**

**PRONE-SLEEPING INFANTS**

Author(s): WATERS KA; GONZALEZ A; JEAN C; MORIELLI A; BROUILLETTE RT

Corporate Source: MONTREAL CHILDRENS HOSP, ROOM C-90, 2300 TUPPER

ST/MONTREAL/PQ H3H 1P3/CANADA/; MONTREAL CHILDRENS

HOSP/MONTREAL/PQ H3H

1P3/CANADA/; MCGILL UNIV, DEPT PEDIAT/MONTREAL/PQ H3A 2T5/CANADA/

Journal: JOURNAL OF PEDIATRICS, 1996, V128, N5 (MAY), P616-625

ISSN: 0022-3476

Language: ENGLISH Document Type: ARTICLE

Abstract: Objective: To determine the frequency and physiologic

consequences of the face-straight-down (FSD) position, a

postulated

mechanism for the sudden infant death syndrome in prone-sleeping  
infants.

Study design: A survey of 151 infants, aged 1 to 7 months, in  
Montreal showed that 33% slept prone. Ten healthy prone-sleeping  
infants were studied in their homes at age 10 to 22 weeks.

**Infrared**

video and cardiorespiratory recordings were made on 3 consecutive  
nights in the prone (nights 1 and 3) and lateral (night 2)  
positions.

Results: Infants maintained the prone position during 17 of 19

studies, but only 4 of 9 infants maintained the lateral position. The FSD position was observed 27 times in 17 prone nights: median frequency, 0.6 times per night (interquartile range, 0 to 4), and median total duration, 3.3 minutes (0.8% of total sleep time). A related position, the face-near-straight-down (FNSD) position, occurred more often, 5.3 (1 to 10) times per prone night, for 22.4 minutes (5.8% of total sleep time). Most periods in the FSD or FNSD position had no physiologic consequences; however, 14% of FSD and 3% of FNSD episodes were associated with airway obstruction as indicated by snoring, paradoxical respiratory movements, apnea, and/or increased partial pressure of transcutaneous **carbon dioxide**. Spontaneous arousal and head turning terminated the FSD and FNSD episodes.

Conclusion: The FSD and FNSD positions occur commonly in healthy prone-sleeping infants, and these positions can cause airway obstruction. We speculate that those infants with sudden infant death syndrome found in the FSD or FNSD position either have a congenital or an acquired defect in the arousal-head turning response or have encountered insurmountable environmental factors that prevent effective head turning.

**18/7/5** (Item 3 from file: 34)  
DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2005 Inst for Sci Info. All rts. reserv.

04319239 Genuine Article#: RV455 Number of References: 119  
**Title: SLEEP AND BREATHING - CENTRAL SLEEP-APNEA, PATHOGENESIS AND TREATMENT - AN OVERVIEW AND PERSPECTIVE**  
Author(s): DEBACKER WA  
Corporate Source: UNIV INSTELLING ANTWERP, DEPT PULM MED, UNIV PL 1/B-2610  
WILRIJK//BELGIUM/  
Journal: EUROPEAN RESPIRATORY JOURNAL, 1995, V8, N8 (AUG), P1372-1383  
ISSN: 0903-1936  
Language: ENGLISH Document Type: REVIEW  
Abstract: The prevalence of reported sleep disturbances in a general population is high, Many of the complaints are the result of sleep-related breathing disorders, due mainly to the occurrence of obstructive and central apnoeas, Obstructive sleep apnoea is a fully described and well-recognized entity, Central sleep apnoea (CSA) however, has been poorly studied.

There is accumulating evidence that central sleep apnoea should be considered as the end of a spectrum, Instability in the breathing pattern is the main underlying mechanism and is due to the interaction of many factors, Breathing during sleep is dependent on metabolic control and the activity of the respiratory muscles, Decreased chemical drive and/or failing respiratory muscle function are associated with CSA and usually also with ongoing hypoventilation during wakefulness, characterized by chronic daytime hypercapnia Central respiratory drive can also be inhibited by upper airway reflexes, Mostly, however, CSA occurs as the hallmark of unstable breathing during sleep brought about by an overall increase in loop gain (especially in light sleep stages) and the unmasking of a **CO2 threshold** .

Arousal following central apnoeas acts as an amplification of the instability, Micro electroencephographic (EEG) arousals are often observed as a consequence of CSA, They are responsible for sleep fragmentation and hypersomnolence during the day, The daytime hypersomnolence and complaints of awakenings during sleep in patients with CSA can be striking, CSA can occur in specific pathologies, such as chronic heart failure and (post-traumatic) brain lesions, that are associated with irregular breathing.

Treatment strategies are remarkably few in number, Use of nasal ventilation and the inhalation of **CO2** are mainly of theoretical interest, since patients do not often tolerate these more invasive therapies, Drug treatment, especially with acetazolamide, is easier to perform, Stimulation of upper airway reflexes, by less invasive methods, seems to be promising for the near future.

**18/7/6 (Item 4 from file: 34)**

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2005 Inst for Sci Info. All rts. reserv.

02169204 Genuine Article#: KG019 Number of References: 13

**Title: END-TIDAL CO2 ANALYSIS IN SLEEP-APNEA SYNDROME - CONDITIONS FOR**

**USE**

Author(s): MAGNAN A; PHILIPJOET F; REY M; REYNAUD M; PORRI F; ARNAUD A

Corporate Source: CHU NORD, SERV PNEUMOLOGIE/F-13326 MARSEILLE  
15//FRANCE/;

CHU NORD, SERV PNEUMOLOGIE/F-13326 MARSEILLE 15//FRANCE/; CHU  
NORD, SERV

NEUROPHYSIOL/F-13326 MARSEILLE 3//FRANCE/

Journal: CHEST, 1993, V103, N1 (JAN), P129-131

ISSN: 0012-3692

Language: ENGLISH Document Type: ARTICLE

Abstract: The diagnosis of sleep apnea syndrome (SAS) requires  
expensive

and complex instrumentation. The purpose of the present study was  
to

determine the value of end-tidal **CO2** (EtCO2) in screening for  
sleep

apneas. Thirty-nine patients referred to our sleep laboratory  
because

of suspected SAS and ten normal subjects were studied. The EtCO2  
was

measured using an **infrared** spectrometer (POET) designed for  
simultaneous measurement of CO, and pulse oximetry. In 29  
subjects,

expired gas was sampled with a nasobuccal mask (Respiron) with  
lateral

orifices. In the other 20 subjects, sampling was done with  
nasobuccal

prongs (Criticare) comprising a four-channel plastic tube to the  
mouth

and the nostrils. Data from an 8-h night were transferred the  
following

day to a microcomputer (Apple Macintosh) for processing. Apnea was  
defined as an absence of **detection** of **CO2** for more than 10 s.  
Conventional polysomnography was performed (Respisomnographie). The  
number of apneas in 8 h and the apnea index (number of apneas in 1

h)

were calculated after visual analysis on the screen of the  
polysomnograph and also with EtCO2 analysis. For recordings made  
with a

nasobuccal mask, the regression curve between the apnea indices  
computed with EtCO2 and polysomnography was an order 2 polynomial  
curve

( $r = 0.76$ ;  $p < 0.001$ ), with an inflection point at 39 apneas per  
hour.

For recordings with nasobuccal prongs, the correlation was very  
significant ( $r = 0.95$ ;  $p < 0.0001$ ), and the regression curve was  
linear.

The EtCO2 with nasobuccal prongs appears to be a simple and  
reliable

method for screening for SAS.

18/7/7 (Item 5 from file: 34)

DIALOG(R)File 34:SciSearch(R) Cited Ref Sci  
(c) 2005 Inst for Sci Info. All rts. reserv.

00938137    Genuine Article#: FH216    Number of References: 0  
(NO REFS KEYED)

**Title: ACCURACY OF END-TIDAL CARBON - DIOXIDE TENSION ANALYZERS**

Author(s): RAEMER DB; CALALANG I

Corporate Source: BRIGHAM & WOMENS HOSP, DEPT ANESTHESIA, 75 FRANCIS  
ST/BOSTON//MA/02115

Journal: JOURNAL OF CLINICAL MONITORING, 1991, V7, N2, P195-208

Language: ENGLISH    Document Type: ARTICLE

Abstract: Substantial mean differences between arterial **carbon dioxide**

tension (PaCO<sub>2</sub>) and end-tidal **carbon dioxide** tension (PETCO<sub>2</sub>)  
in

anesthesia and intensive care settings have been demonstrated by a  
number of investigators. We have explored the technical causes of  
error in the measurement of PETCO<sub>2</sub> that could contribute to the  
observed differences. In a clinical setting, the measurement of  
PETCO<sub>2</sub>

is accomplished with one of three types of instruments, **infrared**  
analyzers, mass spectrometers, and Raman spectrometers, whose  
specified

accuracies are typically +/-2, +/- 1.5, and +/- 0.5 mm Hg,  
respectively. We examined potential errors in PETCO<sub>2</sub> measurement  
with

respect to the analyzer, sampling system, environment, and  
instrument.

Various analyzer error sources were measured, including stability,  
warm-up time interference from nitrous oxide and oxygen, pressure,  
noise, and response time. Other error sources, including  
calibration,

resistance in the sample catheter, pressure changes, water vapor,  
liquid water, and end-tidal detection algorithms, were considered  
and

are discussed. On the basis of our measurements and analysis, we  
estimate the magnitude of the major potential errors for an  
uncompensated **infrared** analyzer as: inaccuracy, 2 mm Hg;  
resolution,

0.5 mm Hg; noise, 2 mm Hg; instability (12 hours), 3 mm Hg;  
miscalibration, 1 mm Hg; selectivity (70% nitrous oxide), 6.5 mm  
Hg;

selectivity (100% oxygen), - 2.5 mm Hg; atmospheric pressure  
change, <

1 mm Hg; airway pressure at 30 cm H<sub>2</sub>O, 2 mm Hg; positive end-  
expiratory

pressure or **continuous positive airway pressure** at 20 cm  
H<sub>2</sub>O,

1.5 mm Hg; sampling system resistance, < .1 mm Hg; and water vapor,  
2.5

mm Hg. In addition to these errors, other systematic mistakes  
such as

an inaccurate end-tidal detection algorithm, poor calibration  
technique, or liquid water contamination can lead to gross  
inaccuracies. In a clinical setting, unless the user is confident  
that

all of the technical error sources have been eliminated and the

physiologic factors are known, depending on PETCO<sub>2</sub> to determine PaCO<sub>2</sub>  
is not advised.

18/7/8 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2005 Elsevier Science B.V. All rts. reserv.

12139569 EMBASE No: 2003250503  
Continuous positive airway pressure during bronchoalveolar lavage

in patients with severe hypoxemia

An C.H.; Lim S.Y.; Suh G.Y.; Park G.Y.; Park J.W.; Jeong S.H.; Lim S.Y.;

Oui M.; Koh W.-J.; Chung M.P.; Kim H.; Kwon O.J.

Dr. G.Y. Suh, Div. of Pulmon./Critical Care Med., Department of Medicine,

Samsung Medical Center, 50, Ilwon-Dong, Kangnam-Ku, Seoul, 135-710 South

Korea

AUTHOR EMAIL: gysuh@smc.samsung.co.kr

Tuberculosis and Respiratory Diseases ( TUBERC. RESPIR. DIS. )

(South

Korea) 01 JAN 2003, 54/1 (71-79)

CODEN: KHCHA ISSN: 0378-0066

DOCUMENT TYPE: Journal ; Article

LANGUAGE: KOREAN SUMMARY LANGUAGE: ENGLISH; KOREAN

NUMBER OF REFERENCES: 11

Background: A bronchoalveolar lavage(BAL) is useful in diagnosing the etiology of bilateral pulmonary infiltrations, but may worsen the oxygenation and clinical status in severely hypoxemic patients. This study

assessed the safety and efficacy of the continuous positive airway

pressure ( CPAP ) using a conventional mechanical ventilator via a face

mask as a tool for maintaining the oxygenation level during BAL.

Methods:

Seven consecutive patients with the bilateral pulmonary infiltrates and

severe hypoxemia (PaO<sub>2</sub>/FIO<sub>2</sub> ratio ≤200 on oxygen 10 L/min via mask

with reservoir bag) were enrolled. The CPAP 5-6 cmH<sub>2</sub>O(FS<sub>2</sub>IOS<sub>2</sub> 1.0)

was delivered through an inflatable face mask using a conventional mechanical ventilator. The CPAP began 10 min before starting the BAL and

continued for 30 min after the procedure was completed. A bronchoscope was

passed through a T-adapter and advanced through the mouth. BAL was

performed using the conventional method. The vital signs, pulse oxymetry values, and arterial blood gases were monitored during the study.

Results:

(1) Median age was 56 years (male:female=4:3). (2) The baseline PaOSUB2 was 78+/-16 mmHg, which increased significantly to 269+/-116 mmHg (p=0.018) with

**CPAP**. After the BAL, the PaOSUB2 did not decrease significantly but returned to the baseline **level** after the **CPAP** was discontinued.

The

SpOSUB2 showed a similar trend with the PaOSUB2 and did not decrease to

below 90% during the duration of the study. (3) The PaCOSUB2 increased and

the pH decreased significantly after the BAL but returned to the baseline

**level** within 30 min after the BAL. (5) No complications directly related

to the BAL procedure were encountered. However, intubation was necessary in

3 patients (43 %) due to the progression of the underlying diseases.

Conclusion: In severe hypoxemic patients, **CPAP** using a face mask and conventional mechanical ventilator during a BAL might allow minimal alterations in oxygenation and prevent subsequent respiratory failure.

18/7/9 (Item 2 from file: 73)

DIALOG(R) File 73:EMBASE

(c) 2005 Elsevier Science B.V. All rts. reserv.

11489272 EMBASE No: 2002060719

**Lung carbon dioxide elimination correlates with physiologic dead space volume during mechanical ventilatory support**

Sungur M.; Guven M.

M. Sungur, Erciyes Universitesi Tip Fakultesi, 1c(cedil)

Hastalıkları

ABD, Kayseri 38039 Turkey

Turkish Journal of Medical Sciences ( TURK. J. MED. SCI. ) (Turkey)  
2001, 31/6 (529-532)

CODEN: TJMEE ISSN: 1300-0144

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 10

Increased mean airway pressure (PSUBaw) predisposes to increased alveolar

dead space volume and, hence, physiologic dead space volume (VSUBDphys).

This is the result of overdistending alveoli, converting Zone 2 and Zone 3

units to Zone 1 units. Lung **carbon dioxide** elimination (LCOSUB2) is a

reflection of pulmonary capillary blood flow. It is hypothesized that

as

Zone 1 units form or VSUBDphys increases, LCOSUB2 decreases proportionately

and eventually PaCOSUB2 increases, The purpose of this study is to determine if LCOSUB2 correlates with VSUBDphys during mechanical ventilation. Six sheep (66.3 +/- 6.5 kg), anesthetized with sodium thiopental and paralyzed using pancronium, had pulmonary artery and arterial catheters inserted, and were intubated and ventilated

[Fraction of inspired oxygen of 1.0, controlled mechanical ventilation]. Acute lung injury was induced by tracheal instillation of hydrochloric acid (pH 2.5,

0,25 mL/kg). **Continuous positive airway pressure (CPAP)** levels of

5, 10 and 20 cm HSUB20 were randomly applied. Cardiac output was maintained

nearly constant at all **CPAP0** levels. Data from flow/pressure and **infrared**

capnometer sensors, positioned between the endotracheal tube and the "Y"

piece of the breathing circuit, were directed to a commercially available

respiratory monitor (Novamatrix), which provided real time display of PSUBaw and LCOSUB2 (area under the exhaled volume and COSUB2 curve integrated over 1 min). VSUBDphys and the physiologic dead space volume to

tidal volume ratio (VD/VT), calculated using the single breath COSUB2 elimination technique, were also displayed on the monitor. Data were analyzed using regression analysis; alpha was set at 0.05 for statistical

significance. Conclusion: **CPAP** increases PSUBaw, which correlated positively with VSUBDphys. LCOSUB2 correlated negatively and PaCOSUB2 correlated positively with VSUBD/VSUBT. At VSUBD/VSUBT of approximately

0.5. LCOSUB2 began decreasing and PaCOSUB2 increasing, LCOSUB2 is simple to

measure, and real time data provides useful clinical information, i.e., a

noninvasive inference of changes in VSUBDphys and PaCOSUB2 following application of positive pressure.

**18/7/10 (Item 3 from file: 73)**

DIALOG(R)File 73:EMBASE

(c) 2005 Elsevier Science B.V. All rts. reserv.

03164144 EMBASE No: 1986141721

**Indirect calorimetry in artificially ventilated children. Part 2: A new device and its test performance in a new developed metabolic lung model**

INDIREKTE KALORIMETRIE BEI BEATMETEN KINDERN. 2. TEIL: EIN MESSVERFAHREN UND SEINE UBERPRUFUNG AN EINEM NEUENTWICKELTEN STOFFWECHSEL-

# LUNGENMODELL

Semsroth M.

Klinik für Anästhesie und Allgemeine Intensivmedizin, A-1090 Wien  
Austria

Infusionstherapie und Klinische Ernährung - Forschung und Praxis (  
INFUSIONSTHER. KLIN. ERNAHR. FORSCH. PRAX. ) (Switzerland) 1985,

12/6

(294-303)

CODEN: IKEFA

DOCUMENT TYPE: Journal

LANGUAGE: GERMAN SUMMARY LANGUAGE: ENGLISH

A new device for continuous measurement of oxygen uptake ( $V_{O_2}$ ) and

**carbon dioxide** elimination ( $V_{CO_2}$ ) in artificially  
ventilated or

**CPAP** -system breathing children has been developed. A dual-channel  
analyzer

system based on zirconium oxide cell measures oxygen fractions. This  
allows

not only single measurements but also continuous determination of  
fraction

differences for oxygen ( $\Delta F_{O_2}$ ) (accuracy  $\pm 0,003$  Vol%).

## **Carbon**

**dioxide** is measured by **infrared** absorption. A mixing device for  
inspiratory gas was designed to smooth fluctuations of inspired oxygen  
fractions almost completely. The reliable sampling system for  
expiratory

gases has already been described. The breathing-e.g. ventilating-  
system was

modified in such a way that the total gas flow is independent of mode  
and

breathing volume (equally 15 l/min). For this purpose we use a self  
aspirating, time-cycled, volume limited respirator or a high-flow-

## **CPAP**

-system. The prototype described ran test performances on a specially  
developed pneumatic metabolic-lung-model. This new lung model enables  
free

choice of respiratory quotient (R) by independent setting of  $V_{O_2}$ -  
uptake

and  $V_{CO_2}$ -elimination. Under these controlled laboratory conditions  
gas

volume-balances correspond to expected values in children as shown  
during

simulated trials. In the metabolic-lung-model accuracy and  
reproduction

averaged  $\pm 1\%$  for  $V_{CO_2}$ . Both were independent of the mode of  
ventilatory support,  $F_{I_{O_2}}$ , and R. Determinations of  $V_{O_2}$   
were

more dependent on  $F_{I_{O_2}}$  and R. After computing primary data  
according

to a special formula which equalizes differences between  $V_{(I)}$  and  $V_{(E)}$

the maximal error was  $\pm 7\%$ . Maximum difference between preset and

measured R-values ranging from 0.769 to 1.429 was -4.6%, determined at R = 1.429. By means of this independent test series insights into clinically expected measurement errors and dimensions of limits of accuracy could be demonstrated. It seems to be justified that our newly developed device for accurately measuring O<sub>2</sub>-uptake and CO<sub>2</sub>-elimination is highly recommendable for use in extremely difficult conditions as in ventilated children.

**18/7/11 (Item 1 from file: 155)**

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2005 The Dialog Corp. All rts. reserv.

07485938 PMID: 3937811

**[Indirect calorimetry in artificially respired children. 2. A measuring procedure and its evaluation in a newly developed metabolism-lung model]**

Indirekte Kalorimetrie bei beatmeten Kindern. 2. Teil Ein Messverfahren und seine Überprüfung an einem neuentwickelten Stoffwechsel-Lungenmodell.

Semsroth M

Infusionstherapie und klinische Ernährung (SWITZERLAND) Dec 1985, 12

(6) p294-303, ISSN 0378-0791 Journal Code: 7613112

Publishing Model Print

Document type: Journal Article ; English Abstract

Languages: GERMAN

Main Citation Owner: NLM

Record type: MEDLINE; Completed

A new device for continuous measuring oxygen uptake (VO<sub>2</sub>) and carbondioxide elimination (VCO<sub>2</sub>) in artificially ventilated or **CPAP**

-system breathing children has been developed. A dual-channel analyzer system based on zirconiumoxyd cells measures oxygen fractions. This allows not only single measurements but also continuous determination of fraction differences for oxygen (delta FO<sub>2</sub>) (accuracy +/- 0.003 Vol%). Carbondioxide is measured by **infrared** absorption. A mixing device for inspiratory gas was designed to smooth fluctuations of inspired oxygen fractions almost completely. The reliable sampling system for expiratory gases has

already  
been described [19]. The breathing-e.g. ventilating-system was  
modified in  
such a way that the total gas flow is independent of mode and  
breathing  
volume (equally 15 l/min). For which purpose we use a self  
aspirating,  
time-cycled, volume limited respirator or a high-flow- **CPAP** -  
system. The  
prototype described ran test performances on a specially  
developed  
pneumatic metabolic-lung-model. This new lung model enables free  
choice of  
respiratory quotient (R) by independent setting of O<sub>2</sub>-uptake and  
**CO<sub>2</sub>**  
-elimination. Under these controlled laboratory  
conditions  
gasvolume-balances correspond to expected values in children  
really as  
shown during simulated trials. In the metabolic-lung-model  
accuracy and  
reproduction averaged  $\pm 1\%$  for VCO<sub>2</sub>. Both were independent of the  
mode of  
ventilatory support, FIO<sub>2</sub>, and R. Determinations of VO<sub>2</sub> were more  
dependent  
on FIO<sub>2</sub> and R. After computing primary data according to a special  
formula  
which equalizes differences between V<sub>I</sub> and V<sub>E</sub> the maximal error was  
 $\pm 7\%$ .  
Maximum difference between preset and measured R-values ranging from  
0.769  
to 1.429 was -4.6%, determined at R = 1.429. By means of this  
independent  
test series insights into clinically expected measurement  
errors and  
dimensions of limits of accuracy could be demonstrated. It seems  
to be  
justified that our newly developed device for accurate measuring O<sub>2</sub>-  
uptake  
and **CO<sub>2</sub>** -elimination is highly recommendable for use in  
extremely  
difficult conditions as in ventilated children.

Record Date Created: 19860410

Record Date Completed: 19860410

**18/7/12 (Item 1 from file: 35)**

DIALOG(R)File 35:Dissertation Abs Online

(c) 2005 ProQuest Info&Learning. All rts. reserv.

01270267 ORDER NO: NOT AVAILABLE FROM UNIVERSITY MICROFILMS INT'L.

**SLEEP RELATED RESPIRATORY DISORDERS IN PATIENTS WITH CHRONIC  
OBSTRUCTIVE**

**PULMONARY DISEASE (COPD) AND OBSTRUCTIVE SLEEP APNEA SYNDROME (OSAS):**

**EFFECTS OF CONTINUOUS POSITIVE AIRWAY PRESSURE VIA THE NOSE  
(N-CPAP), ALONE AND ASSOCIATED WITH OXYGEN**

Original Title: ALTERACIONES RESPIRATORIAS DURANTE EL SUENO EN  
PACIENTES

AFFECTOS DE BRONQUITIS CRONICA OBSTRUCTIVA Y SINDROME DE APNEAS  
OBSTRUCTIVAS DEL SUENO. EFECTOS DE LA APLICACION DE PRESION  
POSITIVA

CONTINUA EN LAS VIAS AEREAS POR VIA NASAL, SOLA Y ASOCIADA A  
OXIGENOTERAPIA

Author: SAMPOL RUBIO, GABRIEL

Degree: MED.D.

Year: 1990

Corporate Source/Institution: UNIVERSITAT AUTONOMA DE BARCELONA  
(SPAIN)  
(5852)

Source: VOLUME 54/01-C OF DISSERTATION ABSTRACTS INTERNATIONAL.  
PAGE 205. 180 PAGES

Language: SPANISH

ISBN: 84-7488-888-3

Publisher: SERVEI DE PUBLICACIONS DE LA UNIVERSITAT AUTONOMA DE  
BARCELONA, EDIFICI RECTORAT, APARTAT POSTAL 20, E-

08193

BELLATERRA (BARCELONA), SPAIN

In order to know the sleep related respiratory disorders in  
patients  
with COPD + OSAS, the effects of n- **CPAP** and the feasibility of  
associated  
oxygen with n- **CPAP** were studied in 16 men affected with both  
diseases  
during three consecutive nights.

On the first night we performed a polysomnography  
(electroencephalogram + electro-oculogram + chin electromyogram +  
respiratory thoracic and abdominal effort by inductance  
plethysmography +  
detection of airflow + electrocardiogram + arterial oxygenation by  
pulse  
**oximetry** ); 2nd night: polysomnography + progressive pressure **levels**  
of  
n- **CPAP** + radial artery catheterization; 3rd night: polysomnography +  
n-  
**CPAP** + oxygen applied into the mask of n- **CPAP** + radial catheter.

Mean apnea-hypopnea index was 47 (25), hypopneas were frequent:  
in 8  
patients their number were greater than the number of apneas, and four  
of  
them had an apnea index  $\leq 1$  apnea/hour of sleep. All the patients  
presented desaturations caused by apnea or hypopnea. Furthermore they  
also  
presented desaturations not related to these events with a mean  
frequency  
of 17.6 (12.6) during n-REM sleep) and 10.7 (13.1) (during REM sleep)

and a duration greater than the observed in the desaturations caused by apnea or hypopnea. Desaturations secondary to apnea were the most severe during n-REM sleep as during REM sleep. Mean desaturation time was 39.7% (19).

The use of n- **CPAP** during the second night limited apneas, hypopneas and, by an unknown mechanism of action, the desaturations not related to apnea or hypopnea that showed a change from 17.6 (12.6) desaturations/hour to 4.4 (6) ( $p \leq 0.01$ ) during n-REM sleep and from 9.2 (6) to 5.2 (5) ( $p$ :n.s.) during REM sleep.

Despite the limitation of apneas, hypopneas and desaturations the application of n- **CPAP** did not achieve a correct hemoglobin oxygen saturation (SaO<sub>2</sub>) during sleep in our patients: 86.2% (5) (n-REM) and 83.6%

(7.1) (REM). The association of oxygen, 1.5 (0.2) l/min, to n- **CPAP** showed to be effective: SaO<sub>2</sub> increased to a mean value of 92.5% (2) ( $p \leq 0.01$ )

without involving greater values of arterial **carbon dioxide** or cardiac arrhythmias.

?

13/3,K/4 (Item 4 from file: 149)  
DIALOG(R)File 149:TGG Health&Wellness DB(SM)  
(c) 2005 The Gale Group. All rts. reserv.

01479799 SUPPLIER NUMBER: 15250307 (USE FORMAT 7 OR 9 FOR FULL TEXT)

**Synchronized intermittent mandatory ventilation with and without pressure support ventilation in weaning patients with COPD from mechanical ventilation.**

Jounieaux, Vincent; Duran, Alain; Levi-Valensi, Pierre  
Chest, v105, n4, p1204(7)  
April,  
1994

PUBLICATION FORMAT: Magazine/Journal ISSN: 0012-3692 LANGUAGE: English  
RECORD TYPE: Fulltext TARGET AUDIENCE: Professional  
WORD COUNT: 4058 LINE COUNT: 00424

TEXT:

...intermittent mandatory ventilation (SIMV) with pressure support ventilation (PSV) (group 1) or SIMV alone (group 2). The volumetric support of ventilation (SIMV rate) was progressively **decreased** in both groups according to the patient's tolerance with a concurrent **decrease** in the barometric support of ventilation (PSV levels from 15 cm [H.sub.2]O to 6 cm [H.sub.2]O). At each step...

... patients with COPD often do not tolerate discontinuation of mechanical ventilation (MV) due to the combination of a number of factors.[3] During ARF, the **increase** in both inspiratory and expiratory flow resistances results in an **increased** mechanical load for the respiratory muscles, and leads to intrinsic positive end-expiratory pressure (PEEP) which acts as an inspiratory threshold load. Concurrently, the hyperinflation...

...diaphragm which then operates on a less efficient portion of its force-length curve.[4] So, COPD patients in ARF have to cope with an **increased** work of breathing that has to be overcome by respiratory muscles which are in a disadvantageous position.[5] Furthermore, MV itself may aggravate intrinsic PEEP,[6] may **increase** the mechanical load by the resistances of endotracheal tube and respirator circuitry,[7] and can be so considered as an additional burden for the respiratory...

...constant preset positive airway pressure during spontaneous inspiration. As in IMV, spontaneous breathing with PSV requires the patient to open the demand valve which might **increase** the work of breathing.[12] However, Brochard and coworkers[13] have shown that PSV reduces significantly the work imposed on the respiratory muscles. Therefore, an...

...performed. When patients with COPD had successfully undergone this procedure, they were extubated.

In group 1, PSV was added throughout the weaning period and four **decreasing** levels, arbitrarily chosen, were used concurrently with the **decrease** in SIMV rate: 15 cm [H.sub.2]O at 10 cycles/min step; 12 cm [H.sub.2]O at 8 cycles/min step...airways pressure exceeds the PSV level by 1.5 cm [H.sub.2]O. In both groups, appearance of clinical signs of respiratory muscle fatigue ( **increased** in spontaneous breathing frequency [Sf], alternating abdominal and rib cage breathing, paradoxical inspiratory inward motion of the anterior wall of the abdomen, or sweats),[17...

...H.sub.2]O). No sedative, narcotic, or analeptic drugs were administered.

Measurements

At each step of SIMV rate (ie, at each 2 cycles/min **decrease** ), several measurements were performed when a ventilatory steady state was achieved on semirecumbent position: average systolic blood pressure (SBP)

and heart rate (HR) from repeated...

...were evaluated and arterial blood gases were sampled when the steady state was achieved for the step.

The oxygen cost of breathing (OCB) was concurrently **determined** by a technique of indirect calorimetry similar to that of Harpin and coworkers.[18] Inspired and expired gas samples were taken, respectively, from the inspiratory and expiratory lines of the respirator. Oxygen and **carbon dioxide levels** were continuously **measured** using, respectively, a polarographic and an **infrared** gas analyzer (Ergotest Jager with sensitivity of [+ or -] 0.02 percent, two-point gas calibration done before each run) during two periods of 5 min and average values **calculated**. All volumes were corrected to STPD conditions. Oxygen consumption ( $[VO_{sub.2}]$ ) was evaluated using the following equation:

[Mathematical Expression Omitted] where  $[FEO_{sub.2}]$  period (SB period),  $S_f$  and  $sVE$  significantly **increased** in both groups concurrently to the recovery in respiratory autonomy (Fig 2). In the SIMV/PSV group,  $sVT$  remained constant throughout the study despite **decreasing** levels of PSV (Fig 1) and no correlation was found between the PSV levels and  $sVT$ . In group 2 patients,  $sVT$  did not change throughout...

...SIMV/PSV and SIMV groups in the OCB ( $[VO_{sub.2}]_{resp}$  and  $[VO_{sub.2}]_{resp}$  percent, Fig 3). Of course, the OCB significantly **increased** in both groups from F.10 step to SB step concurrently to the **increase** of the spontaneous ventilation (Fig 3). When the  $[VO_{sub.2}]$  is expressed per liter of ventilation, it significantly **increased** from F.10 step to SB step in patients without PSV, whereas it **decreased** in patients with PSV (Table 3 and Fig 4).

At the end of this study, all patients with COPD were extubated as they had undergone...

...new criteria have not been independently validated.

Because we had been unable to successfully wean or extubate these patients, we decided to propose a gradual **decrease** in both the volumetric (SIMV) and barometric (PSV) assistances of ventilation during the weaning period. The SIMV rate was **decreased** in a standard way, once or twice a day, depending on the patient's tolerance. This was based on published clinical signs of respiratory muscle...

...the oxygen cost of spontaneous breathing. This is usually less than 5 percent of the  $[VO_{sub.2}]_{tot}$  in normal subjects breathing quietly, but **increases** in patients with COPD and in patients undergoing artificial ventilation.[26] Indeed, we found high values of OCB in COPD patients when breathing spontaneously via...the respirator (Puritan Bennett 7200) induces an additional inspiratory work ranging from 10 to 40 percent. Fiastro and coworkers[37] predicted that a 1-mm **decrease** in the tube diameter results in a 67 to 100 percent **increase** in this work. Nevertheless, low PSV level (6 cm  $[H_{sub.2}]_O$  or 8 cm  $[H_{sub.2}]_O$ ) did not significantly **decrease** the OCB of our patients.

The only objective benefit of PSV appeared when considering  $[VO_{sub.2}]_{resp}/SVE$  which represents the oxygen cost per liter of spontaneous ventilation and expresses the efficiency of the ventilation.[18] The  $[VO_{sub.2}]_{resp}/SVE$  significantly **decreased** across the weaning period in group 1 whereas it significantly **increased** in group 2 (Table 3 and Fig 4). Pressure support ventilation could improve the efficiency of the ventilation when added to SIMV. As PSV had...

...and accelerated the recovery in lung mechanics. This could explain why  $sVT$  remained constant throughout the weaning period despite the degressive PSV levels and the **decrease** in  $[VO_{sub.2}]_{resp}/SVE$ . Nevertheless, these

suggestions remain speculative as we did not measure the lung mechanics.  
The interpretation of our results depends...27

[31] Viale JP, Annat GJ, Bouffard YM, Delafosse BX, Bertrand OM, Motin JP. Oxygen cost of breathing in postoperative patients: pressure support ventilation versus **continuous positive airway pressure** . Chest 1988; 93:506-09

[32] MacIntyre NR, Nishimura M, Usada Y, Tokioka H, Takezawa J, Shimida Y. The Nagoya conference on system design and...

...with inspiratory pressure support. Am Rev Respir Dis 1987; 136:411-15

[36] Katz JA, Kraemer RW, Gjerde GE. Inspiratory work and airway pressure with **continuous positive airway pressure** delivery systems. Chest 1985; 88:519-26

[37] Fiastro JF, Habib MP, Quan SF. Pressure support compensation for inspiratory work due to endotracheal tubes and demand **continuous positive airway pressure** . Chest 1988; 93:499-505

? ds;show files

Set	Items	Description
S1	26	AU='RICHEY J B'
S2	277	CPAP OR CONTINUOUS?() POSITIVE() (AIR OR AIRWAY) () PRESSURE? ?
S3	1	S1 AND S2
S4	1014466	SENS???
S5	95330	CARBON() DIOXIDE OR CO2
S6	116772	INFRARED OR INFRA() RED
S7	1264	S4 (3N) S5
S8	1	S6 AND S7 AND S2

File 347: JAPIO Nov 1976-2005/Feb (Updated 050606)  
(c) 2005 JPO & JAPIO

File 350: Derwent WPIX 1963-2005/UD, UM & UP=200539  
(c) 2005 Thomson Derwent

? ds;show files

Set	Items	Description
S1	16176	CONTINUOUS() POSITIVE
S2	416653	VENTILAT?
S3	2274	S1(5N)S2
S4	14555	CONTINUOUS?() POSITIV?() (AIR OR AIRWAY?) () PRESSUR?
S5	10662	CPAP
S6	17951	S4 OR S5
S7	507481	CARBON() DIOXIDE OR CO2
S8	812	S6 AND S7
S9	10043312	LEVEL? OR THRESHOLD? OR PARAMETER?
S10	17987	S7(5N)S9
S11	29	S8 AND S10
S12	15	RD (unique items)
S13	6888417	THRESHOLD? OR VALUE? OR PARAMETER?
S14	7444007	LEVEL? ?
S15	13782	S7(5N)S14
S16	16	S6 AND S15
S17	8	S13 AND S16
S18	4	RD (unique items)
S19	32036	THRESHOLD(2N)VALUE?
S20	27	S15 AND S19
S21	0	S6 AND S20
File	5: Biosis Previews(R) 1969-2005/Jun W2	(c) 2005 BIOSIS
File	34: SciSearch(R) Cited Ref Sci 1990-2005/Jun W2	(c) 2005 Inst for Sci Info
File	434: SciSearch(R) Cited Ref Sci 1974-1989/Dec	(c) 1998 Inst for Sci Info
File	73: EMBASE 1974-2005/Jun 16	(c) 2005 Elsevier Science B.V.
File	155: MEDLINE(R) 1951-2005/Jun W2	(c) format only 2005 The Dialog Corp.
File	94: JICST-EPlus 1985-2005/Apr W4	(c) 2005 Japan Science and Tech Corp(JST)
File	144: Pascal 1973-2005/Jun W1	(c) 2005 INIST/CNRS
File	35: Dissertation Abs Online 1861-2005/May	(c) 2005 ProQuest Info&Learning
File	441: ESPICOM Pharm&Med DEVICE NEWS 2005/May W3	(c) 2005 ESPICOM Bus.Intell.

?

? ds;show files

Set	Items	Description
S1	17736	CPAP OR CONTINUOUS() POSITIVE() AIRWAY() PRESSURE?
S2	507481	CARBON() DIOXIDE OR CO2
S3	1418956	SENSE? ? OR SENSOR OR SENSING
S4	2089	S3(5N)S2
S5	4446744	DETECT???
S6	3878	S5(5N)S2
S7	0	S1 AND S4
S8	3	S1 AND S6
S9	2	RD (unique items)
S10	31362	OXIMET?
S11	53	S1 AND S2 AND S10
S12	28	RD (unique items)
S13	10043312	THRESHOLD? OR LEVEL? OR PARAMETER?
S14	5	S12 AND S13
S15	568528	INFRARED?
S16	8	S1 AND S2 AND S15
S17	6	RD (unique items)
S18	12	S9 OR S14 OR S17
File	5: Biosis Previews(R) 1969-2005/Jun W2	(c) 2005 BIOSIS
File	34: SciSearch(R) Cited Ref Sci 1990-2005/Jun W2	(c) 2005 Inst for Sci Info
File	434: SciSearch(R) Cited Ref Sci 1974-1989/Dec	(c) 1998 Inst for Sci Info
File	73: EMBASE 1974-2005/Jun 16	(c) 2005 Elsevier Science B.V.
File	155: MEDLINE(R) 1951-2005/Jun W2	(c) format only 2005 The Dialog Corp.
File	94: JICST-EPlus 1985-2005/Apr W4	(c) 2005 Japan Science and Tech Corp(JST)
File	144: Pascal 1973-2005/Jun W1	(c) 2005 INIST/CNRS
File	35: Dissertation Abs Online 1861-2005/May	(c) 2005 ProQuest Info&Learning
File	441: ESPICOM Pharm&Med DEVICE NEWS 2005/May W3	(c) 2005 ESPICOM Bus.Intell.

? ds;show files

Set	Items	Description
S1	20604	CPAP OR CONTINUOUS() POSITIVE() (AIR OR AIRWAY) () PRESSURE
S2	686343	CARBON() DIOXIDE OR CO2
S3	9773822	LEVEL? ?
S4	3771798	THRESHOLD? ? OR PARAMETER? ?
S5	14537570	INCREAS??? OR DECREAS???
S6	3491879	PRESSURE? ?
S7	18681234	SENS??? OR DETERMIN? OR MEASUR??? OR CALCULAT???
S8	828149	INFRARED OR OXIMET?
S9	15232	S2(3N)S3
S10	4814	S7(S)S9
S11	14	S1 AND S5 AND S10
S12	4	S8 AND S11
S13	4	RD (unique items)
S14	366	S7 AND S2 AND S3 AND S1
S15	110	S8 AND S14
S16	71	S4 AND S15
S17	68	RD (unique items)
S18	6614	S2()S3
S19	1841	S5 AND S7 AND S18
S20	14	S1 AND S4 AND S19
S21	14	RD (unique items)
S22	23	S11 OR S21
S23	20	RD (unique items)
S24	17795157	ANALYS? OR ANALYZ?
S25	923593	ANALIS? OR ANALIZ?
S26	17888879	S24 OR S25
S27	2566273	GAS
S28	186966	S27(2N)S26
S29	3687	S8(5N)S28
S30	1033	S2 AND S29
S31	9	S1 AND S30
S32	9	RD (unique items)
S33	8	S32 NOT S22
File	5: Biosis Previews(R)	1969-2005/Jun W2 (c) 2005 BIOSIS
File	34: SciSearch(R) Cited Ref Sci	1990-2005/Jun W3 (c) 2005 Inst for Sci Info
File	35: Dissertation Abs Online	1861-2005/May (c) 2005 ProQuest Info&Learning
File	48: SPORTDiscus	1962-2005/Dec (c) 2005 Sport Information Resource Centre
File	65: Inside Conferences	1993-2005/Jun W3 (c) 2005 BLDSC all rts. reserv.
File	71: ELSEVIER BIOBASE	1994-2005/Jun W2 (c) 2005 Elsevier Science B.V.
File	73: EMBASE	1974-2005/Jun 21 (c) 2005 Elsevier Science B.V.
File	91: MANTIS(TM)	1880-2005/Jun 2001 (c) Action Potential
File	94: JICST-EPlus	1985-2005/May W1 (c) 2005 Japan Science and Tech Corp(JST)
File	98: General Sci Abs/Full-Text	1984-2004/Dec (c) 2005 The HW Wilson Co.
File	135: NewsRx Weekly Reports	1995-2005/Jun W2 (c) 2005 NewsRx
File	144: Pascal	1973-2005/Jun W2 (c) 2005 INIST/CNRS
File	149: TGG Health&Wellness DB(SM)	1976-2005/Jun W2

(c) 2005 The Gale Group  
File 155:MEDLINE(R) 1951-2005/Jun W3  
(c) format only 2005 The Dialog Corp.  
File 156:ToxFile 1965-2005/Jun W3  
(c) format only 2005 The Dialog Corporation  
File 159:Cancerlit 1975-2002/Oct  
(c) format only 2002 Dialog Corporation  
File 162:Global Health 1983-2005/May  
(c) 2005 CAB International  
File 164:Allied & Complementary Medicine 1984-2005/Jun  
(c) 2005 BLHCIS  
File 172:EMBASE Alert 2005/Jun 21  
(c) 2005 Elsevier Science B.V.  
File 266:FEDRIP 2005/Jun  
Comp & dist by NTIS, Intl Copyright All Rights Res  
File 369:New Scientist 1994-2005/May W1  
(c) 2005 Reed Business Information Ltd.  
File 370:Science 1996-1999/Jul W3  
(c) 1999 AAAS  
File 399:CA SEARCH(R) 1967-2005/UD=14226  
(c) 2005 American Chemical Society  
File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec  
(c) 1998 Inst for Sci Info  
File 444:New England Journal of Med. 1985-2005/Jun W1  
(c) 2005 Mass. Med. Soc.  
File 467:ExtraMED(tm) 2000/Dec  
(c) 2001 Informania Ltd.